Developer docs
API playgroundTry for free, no card

Search company profiles

AvengeBio

Full company profile

uuid0002ew7

Namestring
AvengeBio
Legal namestring
Avenge Bio
Websiteurl
avengebio.com
Company typeenum
Private
Founded yearint
2019
Short descriptiontext

AvengeBio is a private Cambridge, MA biotech developing the proprietary LOCOcyte™ cell immunotherapy platform, with lead candidate AVB-001 advancing into clinical trials for metastatic peritoneal cancers, initially ovarian cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cancer immunotherapy, cell therapy platform, solid tumor treatment, peritoneal cancer therapy, biopharmaceutical R&D
Industry3 codes
1CAR-T & TCR-T Therapies
CodeHLAAABACPrimaryYes
2Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
CodeHLAAANAKPrimaryNo
3Therapeutic Vaccines (cancer, chronic infection immunotherapy)
CodeHLAAAEABPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy
Social media profiles2 records
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AvengeBio is developing the proprietary LOCOcyte™ cell-generated immunotherapy platform, a technology designed to engineer cell-based treatments that target and eradicate solid tumors. Its lead product candidate, AVB-001, is being advanced into clinical trials for metastatic peritoneal cancers with a primary focus on ovarian cancer, with the pipeline positioned for expansion into additional solid tumor indications.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1AVB-001
CategoryOncology therapeutic candidate
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Peers10 records
1Iovance Biotherapeutics
TypeDirect peer
Description

Iovance is the leading developer of tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors, with an approved therapy (Amtagvi) for melanoma. Directly comparable to AvengeBio's mission of using cell-based immunotherapies to eradicate solid tumors.

2Adaptimmune Therapeutics
TypeDirect peer
Description

Adaptimmune develops engineered SPEAR T-cell receptor (TCR) therapies targeting solid tumors. Comparable cell therapy platform approach for solid tumor indications, including efforts in ovarian and other solid tumors.

3Lyell Immunopharma
TypeDirect peer
Description

Lyell is developing next-generation cell therapies for solid tumors with technologies addressing T-cell exhaustion and persistence. Directly comparable mission and stage to AvengeBio's LOCOcyte platform.

4Fate Therapeutics
TypeDirect peer
Description

Fate develops off-the-shelf, iPSC-derived cell therapies (NK and T-cell programs) for cancer. Comparable cell therapy platform with multiple solid tumor and hematologic programs in clinical development.

5Marker Therapeutics
TypeDirect peer
Description

Marker develops multi-tumor-associated antigen (TAA)-specific T-cell therapies for solid tumors and lymphoma. Comparable autologous cell therapy approach targeting solid tumor indications.

6Poseida Therapeutics
TypeDirect peer
Description

Poseida develops CAR-T and other cell therapies with proprietary non-viral manufacturing, including programs for solid tumors. Comparable cell therapy platform company at similar stage of clinical development.

7Allogene Therapeutics
TypeBroad incumbent
Description

Allogene is a clinical-stage leader in allogeneic CAR-T cell therapies with broad pipeline across hematologic and solid tumors. Larger, more advanced cell therapy peer in the same technology category.

8Cellectis
TypeDirect peer
Description

Cellectis develops genome-edited allogeneic CAR-T cell therapies using its proprietary TALEN platform. Comparable cell therapy platform with similar technology approach and clinical stage.

9Caribou Biosciences
TypeDirect peer
Description

Caribou develops allogeneic CAR-T cell therapies using CRISPR genome editing, with programs in hematologic malignancies and solid tumors. Comparable cell therapy platform technology and clinical stage.

10Ziopharm Oncology
TypeEmerging player
Description

Ziopharm develops cell and gene therapies for solid tumors, including TCR-T programs using its non-viral Sleeping Beauty platform. Comparable cell therapy approach with focus on solid tumor indications.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AvengeBio

Cancer Immunotherapyavengebio.com

AvengeBio is a private Cambridge, MA biotech developing the proprietary LOCOcyte™ cell immunotherapy platform, with lead candidate AVB-001 advancing into clinical trials for metastatic peritoneal cancers, initially ovarian cancer.

AvengeBio firmographics

Firmographics
Name
AvengeBio
Legal name
Avenge Bio
Website
https://avengebio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
AvengeBio is a private Cambridge, MA biotech developing the proprietary LOCOcyte™ cell immunotherapy platform, with lead candidate AVB-001 advancing into clinical trials for metastatic peritoneal cancers, initially ovarian cancer.
Ownership category
akta.pro rank

AvengeBio industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
CAR-T & TCR-T Therapies (HLAAABAC)
akta.pro secondary industries
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

Keywords

  • Cancer immunotherapy
  • Cell therapy platform
  • Solid tumor treatment
  • Peritoneal cancer therapy
  • Biopharmaceutical R&D

Where AvengeBio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

AvengeBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

AvengeBio product offering

Product offering

Core offering

AvengeBio is developing the proprietary LOCOcyte™ cell-generated immunotherapy platform, a technology designed to engineer cell-based treatments that target and eradicate solid tumors. Its lead product candidate, AVB-001, is being advanced into clinical trials for metastatic peritoneal cancers with a primary focus on ovarian cancer, with the pipeline positioned for expansion into additional solid tumor indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • AVB-001

Companies that use AvengeBio

Customer profile

Segments1 record

Ideal customer profiles2 records

AvengeBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

AvengeBio partnerships and signals

Strategic signal

Scale indicators1 record

AvengeBio competitors and assessment

Company assessment

Direct peers

  • Iovance Biotherapeutics: Iovance is the leading developer of tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors, with an approved therapy (Amtagvi) for melanoma. Directly comparable to AvengeBio's mission of using cell-based immunotherapies to eradicate solid tumors.
  • Adaptimmune Therapeutics: Adaptimmune develops engineered SPEAR T-cell receptor (TCR) therapies targeting solid tumors. Comparable cell therapy platform approach for solid tumor indications, including efforts in ovarian and other solid tumors.
  • Lyell Immunopharma: Lyell is developing next-generation cell therapies for solid tumors with technologies addressing T-cell exhaustion and persistence. Directly comparable mission and stage to AvengeBio's LOCOcyte platform.
  • Fate Therapeutics: Fate develops off-the-shelf, iPSC-derived cell therapies (NK and T-cell programs) for cancer. Comparable cell therapy platform with multiple solid tumor and hematologic programs in clinical development.
  • Marker Therapeutics: Marker develops multi-tumor-associated antigen (TAA)-specific T-cell therapies for solid tumors and lymphoma. Comparable autologous cell therapy approach targeting solid tumor indications.
  • Poseida Therapeutics: Poseida develops CAR-T and other cell therapies with proprietary non-viral manufacturing, including programs for solid tumors. Comparable cell therapy platform company at similar stage of clinical development.
  • Cellectis: Cellectis develops genome-edited allogeneic CAR-T cell therapies using its proprietary TALEN platform. Comparable cell therapy platform with similar technology approach and clinical stage.
  • Caribou Biosciences: Caribou develops allogeneic CAR-T cell therapies using CRISPR genome editing, with programs in hematologic malignancies and solid tumors. Comparable cell therapy platform technology and clinical stage.

Broad incumbents

  • Allogene Therapeutics: Allogene is a clinical-stage leader in allogeneic CAR-T cell therapies with broad pipeline across hematologic and solid tumors. Larger, more advanced cell therapy peer in the same technology category.

Emerging players

  • Ziopharm Oncology: Ziopharm develops cell and gene therapies for solid tumors, including TCR-T programs using its non-viral Sleeping Beauty platform. Comparable cell therapy approach with focus on solid tumor indications.

Market position

Customer concentration

AvengeBio social profiles

Digital presence

AvengeBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AvengeBio leadership team

Management profile

Number of profiles

Profiles3 records

AvengeBio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AvengeBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AvengeBio

What does AvengeBio do?

AvengeBio is developing the proprietary LOCOcyte™ cell-generated immunotherapy platform, a technology designed to engineer cell-based treatments that target and eradicate solid tumors. Its lead product candidate, AVB-001, is being advanced into clinical trials for metastatic peritoneal cancers with a primary focus on ovarian cancer, with the pipeline positioned for expansion into additional solid tumor indications.

Is AvengeBio a public or private company?

AvengeBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was AvengeBio founded?

AvengeBio was founded in 2019. It employs 11 to 50 people.

Where is AvengeBio based?

AvengeBio is headquartered in Cambridge, United States, in the North America region.

Who are AvengeBio's main competitors?

Direct peers on record are Iovance Biotherapeutics, Adaptimmune Therapeutics, Lyell Immunopharma, Fate Therapeutics, Marker Therapeutics, Poseida Therapeutics, Cellectis and Caribou Biosciences. Allogene Therapeutics is listed as a broad incumbent. Ziopharm Oncology is listed as an emerging player.

Does AvengeBio have an API?

No public API is recorded for AvengeBio.

What industry is AvengeBio in?

AvengeBio's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRice Biotech Launch Pad accelerator aims to rapidly turn medical and health discoveries into curesRice University launched the Rice Biotech Launch Pad, a Houston-based accelerator designed to expedite the commercialization of medical and health technology discoveries from its faculty. Supported by federal grants and philanthropic gifts, the initiative aims to build on past successes like Avenge Bio to create a world-class medical innovation ecosystem in Houston.PR NewswireAvenge Bio Announces Presentations at Two Key Upcoming Annual ConferencesAvenge Bio announced that its posters regarding the LOCOcyte™ platform and AVB-001 candidate were selected for presentation at the Society of Gynecologic Oncology’s 2023 Annual Meeting and the American Association for Cancer Research (AACR) Annual Meeting. The presentations will cover preclinical efficacy data and ongoing phase 1/2 clinical trials for metastatic peritoneal cancers, with contributions from researchers at Avenge Bio, MD Anderson Cancer Center, and Rice University. This announcement highlights the company's progress in developing cell-based immunotherapies for solid tumors.PR NewswireAvenge Bio Receives Positive Feedback from Pre-IND FDA Meeting on Development Path for AVB-001 Mesothelioma Program and Provides Pipeline UpdateAvenge Bio announced it received positive feedback from the FDA regarding the development path for its AVB-001 program targeting pleural malignant mesothelioma, with plans to submit an Investigational New Drug application in the second half of 2023. The company also confirmed the enrollment of the first patient in a Phase 1/2 clinical trial for AVB-001 treating refractory ovarian cancer and highlighted ongoing preclinical work on its AVB-002 program.PR NewswireBioCentriq Announces Successful Tech Transfer From Avenge Bio for Manufacturing of Drug Product AVB-001 Resulting in Dosing of First Patient in Phase 1/2 Clinical TrialBioCentriq announced successful completion of technology transfer for Avenge Bio's investigational drug AVB-001 and initiated manufacturing of clinical-grade material to support the ongoing Phase 1/2 clinical trial. Avenge Bio simultaneously reported that the first patient was dosed on January 9th in the First-in-Human trial evaluating AVB-001 for relapsed refractory ovarian cancer, a notoriously difficult-to-treat cancer ranking fifth in cancer deaths among women. The LOCOcyte platform-based cell therapy generates sustained local concentrations of native IL-2 to provoke an immune response while avoiding systemic immunotherapy toxicities.PR NewswireAvenge Bio to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingAvenge Bio announced that three preclinical abstracts regarding its LOCOcyte™ platform and AVB-001 candidate were selected for presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. The company also confirmed that the FDA cleared its Investigational New Drug application for AVB-001, with Phase 1 clinical trials for platinum-resistant ovarian cancer expected to initiate in Q4 2022. These presentations highlight favorable efficacy and safety profiles in animal models, supporting the transition to human trials.PR NewswireAvenge Bio Announces FDA Clearance of the AVB-001 IND for the Treatment of Ovarian Cancer, a Novel Cellular Therapy Leveraging the LOCOcyte™ Immunotherapy PlatformThe FDA has cleared Avenge Bio's Investigational New Drug application for AVB-001, a novel cellular therapy for the treatment of platinum-resistant ovarian cancer and other peritoneal malignancies. AVB-001 is the first clinical implementation of the company's LOCOcyte immunotherapy platform, which uses alginate capsules containing engineered cells that secrete native IL-2 to generate an immune response against tumors. The Phase 1 clinical trial is expected to initiate in the second half of 2022 at multiple centers.PR NewswireAvenge Bio Announces Peer-Reviewed Publication on Preclinical Proof of Concept for LOCOcyte™ Platform TechnologyAvenge Bio announced a peer-reviewed publication in Science Advances describing preclinical proof-of-concept data for its LOCOcyte immunotherapy platform, developed in collaboration with researchers at Rice University. The study demonstrated that engineered cells producing interleukin-2 (IL-2) achieved 100% tumor burden reduction in mouse models of ovarian cancer after 30 days, with similar efficacy and safety results confirmed in non-human primates. The company, which holds an exclusive license from Rice University and has discussed the technology with the FDA, expects to begin clinical studies in the second half of 2022.VC News DailyAvenge Bio Locks Up $45M in Series AAvenge Bio, an oncology-focused biotechnology company based in Natick, Massachusetts, announced the closing of a $45 million Series A financing round co-led by Perceptive Xontogeny Venture Fund and CAM Capital. The round also included participation from seed investor Longitude Capital and new investors Rock Springs Capital and Pappas Capital. The company plans to use the funds to advance its LOCOcyte platform, which develops cell-based immunotherapeutic products for treating intractable solid tumors by delivering engineered cells directly to the local tumor environment.Pulse 2.0Avenge Bio Raises $45 Million In Series A FundingAvenge Bio raised $45 million in Series A funding co-led by Perceptive Xontogeny Venture Fund and CAM Capital. The proceeds will advance its lead program AVB-001 toward an IND filing for recurrent ovarian cancer and expand its pipeline for lung and breast cancers.FinSMEsAvenge Bio Closes $45M Series A FinancingAvenge Bio raised $45M in Series A funding led by Perceptive Xontogeny Venture Fund and CAM Capital. The company will use the funds to advance its lead program AVB-001 for metastatic peritoneal cancers, including ovarian cancer, and continue pipeline development.